Onychomysosis
☆ AI Dermatology — Free Service
Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Uzipho ezichatshazelekayo zibangelwa yi-Onychomycosis
Unyawo lomntu olunesulelo lwezinzipho zokungunda kwiiveki ezilishumi kwikhosi yonyango lomlomo lwe‑terbinafine. Qaphela ukuba iinzipho eziphilileyo ziyakhula emva kweenzipho ezisusiweyo.
relevance score : -100.0%
ReferencesI-antifungal ye-systemic iyona esebenzayo kakhulu. Uhlalutyo lwe-Meta lubonisa amazinga okunyanga i-mycotic ngolu hlobo lulandelayo: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole = 48% . Ukonakaliswa kwezikhonkwane okuhambisanayo nakho kwandisa amazinga okunyanga. Unyango lwangaphakathi olune ciclopirox alusebenzi kangako; lunomlinganiselo wokungaphumeleli ongaphezulu kwe-60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
I-Onychomycosis yintsholongwane yefungal echaphazela iinzipho. Xa ibangelwa yi-dermatophytes, ibizwa ngokuba yi tinea unguium. I-Onychomycosis ibandakanya izifo ezibangelwa yi-dermatophytes, igwele kunye nokungunda. Ingxaki yezikhonkwane ebangelwa lusulelo lomngundo ibizwa ngokuba yi nail dystrophy. Nangona inokuchaphazela zombini iinzipho kunye neeminwe, i-toenail onychomycosis ixhaphake kakhulu. Eli nqaku lixubusha iinkalo ezahlukeneyo ze-toenail onychomycosis, njengempembelelo yayo, iintlobo zeklinikhi, izigaba, ukuxilongwa, kunye nonyango. Nangona ingasongela ubomi, i-onychomycosis inokukhokelela kwiingxaki ezinzulu ezifana ne-cellulitis, i-sepsis, ukusuleleka kwamathambo, umonakalo wezicubu kunye nokulahleka kwezipikili.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
iTerbinafine ilwa nosulelo lomngundo ngokuvimba i-squalene epoxidase. Isebenza ngokuchasene neendidi ezininzi zomngundo wolusu, kwaye yamkelwe ukunyanga ukungunda kweenzipho xa ithathwa ngomlomo. Ngelixa uninzi lweziphumo ezingalindelekanga, ezinjengeentloko kunye nemiba yesisu, zincinci kwaye zihamba zodwa, utshintsho lwencasa (dysgeusia) lunokwahluka ukusuka kumncinci ukuya kobunzima; ngamanye amaxesha kukhokelela ekulahlekelweni kobunzima. Utshintsho lwencasa olusisigxina lunqabile, kodwa luxeliwe.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
I-Onychomycosis yintsholongwane yefungal echaphazela izikhonkwane. Malunga ne-90 % yosulelo lwezikhonkwane kunye ne-75 % yosulelo lweminwe lubangelwa ngumngundo (Trichophyton mentagrophytes, Trichophyton rubrum). Iimpawu ziquka ukutshintsha kwemibala yeenzipho, ukujiya, ukuhlukana kwebhedi yeenzipho, kunye nokukhula. Unyango lubandakanya amayeza aselwayo afana ne‑terbinafine okanye i‑itraconazole, kunye nonyango lwangaphakathi olubonelela ngenketho kwiimeko ezithambileyo ukuya kweziphakathi.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
I‑antifungal terbinafine etyiweyo ngomlomo ibonakala ngoyona esebenzayo, kodwa i‑terbinafine inxulumene nesiphumo esibi esibindini.
Onychomycosis yenzeka malunga ne‑10% yabantu abadala, kwaye abachaphazeleka rhoqo. Amadoda achaphazeleka rhoqo kunabafazi. Onychomycosis imele malunga nesiqingatha sesifo sezikhonkwane. Oku kuthetha ukuba ukukhubazeka kweenzwane kunokubangelwa zizizathu ezahlukeneyo ngaphandle kwe‑onychomycosis.
○ Unyango – Amachiza e‑OTC
Kunzima ukunyanga i‑onychomycosis ngamayeza e‑topical kuba kunzima ukuba izidakamizwa zingene kwi‑toenails ezikwiqina.
#Ketoconazole
#Clotrimazole
#Miconazole
#Terbinafine
#Butenafine [Lotrimin]
#Tolnaftate
○ Unyango
Unyango lwexesha elide lufuna ixesha elide de i‑fungus isuswe ngokupheleleyo.
#Terbinafine (oral)
#Itraconazole
#Efinaconazole lacquer [Jublia]
#Ciclopirox lacquer